Get the Stockscreener App
1.20
0.84%
0.01
Bionano Genomics Inc stock is traded at $1.20, with a volume of 118.77K.
It is up +0.84% in the last 24 hours and up +5.26% over the past month.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
See More
Previous Close:
$1.19
Open:
$1.18
24h Volume:
118.77K
Relative Volume:
0.37
Market Cap:
$13.31M
Revenue:
$28.51M
Net Income/Loss:
$-26.40M
P/E Ratio:
-0.2192
EPS:
-5.4756
Net Cash Flow:
$-16.35M
1W Performance:
+4.35%
1M Performance:
+5.26%
6M Performance:
-36.51%
1Y Performance:
-68.00%
1-Day Range:
$1.17
$1.22
1-Week Range:
$1.09
$1.22
52-Week Range:
$1.06
$5.50
Bionano Genomics Inc Stock (BNGO) Company Profile
Name
Bionano Genomics Inc
Sector
Industry
Phone
(858) 888-7600
Address
9540 TOWNE CENTRE DRIVE, SAN DIEGO, CA
Compare BNGO vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNGO
Bionano Genomics Inc
|
1.20 | 13.31M | 28.51M | -26.40M | -16.35M | -5.4756 |
ISRG
Intuitive Surgical Inc
|
452.07 | 160.56B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
154.51 | 43.95B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
74.56 | 36.34B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
44.28 | 35.94B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
224.09 | 32.65B | 5.40B | 1.49B | 1.78B | 10.12 |
Bionano Genomics Inc Stock (BNGO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-10-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-12-22 | Resumed | BTIG Research | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Jun-16-21 | Initiated | BTIG Research | Buy |
| Sep-24-20 | Initiated | Ladenburg Thalmann | Buy |
| Apr-08-20 | Initiated | Oppenheimer | Outperform |
View All
Bionano Genomics Inc Stock (BNGO) Latest News
BNGO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Bionano Genomics, Inc. (BNGO) Stock Price, News, Quote & History - Yahoo! Finance Canada
[ARS] Bionano Genomics, Inc. SEC Filing - Stock Titan
Bionano Genomics (NASDAQ: BNGO) outlines 2026 virtual meeting and proxy votes - Stock Titan
Aug Highlights: Is Bionano Genomics Inc benefiting from interest rate changes2026 Buyback Activity & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma - Bitget
In 211 myeloma samples, OGM found abnormalities older tests missed - Stock Titan
Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2025 earnings call transcript - MSN
Q4 2024 Bionano Genomics Inc Earnings Call Transcript - GuruFocus
Volume Summary: Is Bionano Genomics Inc backed by strong institutional buying2026 PostEarnings & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Profit Review: Is Bionano Genomics Inc part of any ETFWeekly Trade Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Bionano Genomics earnings are imminent; these most accurate analysts revise forecasts ahead of earnings call - MSN
Bionano outlines $30M–$33M revenue target for 2026 with focus on routine user growth and margin expansion - MSN
Bionano Genomics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:BNGO) 2026-03-24 - Seeking Alpha
Bionano Genomics, Inc. (NASDAQ:BNGO) Q4 2025 Earnings Call Transcript - Insider Monkey
Bionano Genomics Reports 2025 Financial Results, Highlights OGM Adoption and Announces 2026 Revenue Outlook - Minichart
Bionano Genomics 2025 Annual Report Highlights: Optical Genome Mapping, Market Expansion, and Risk Factors 57596054 - Minichart
Bionano Q4 2025 slides: margins surge 47% as cost cuts offset revenue dip - Investing.com Canada
Bionano Genomics Inc (BNGO) Q4 2025 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Earnings Call Summary | Bionano Genomics(BNGO.US) Q4 2025 Earnings Conference - Moomoo
Bionano Genomics Inc (BNGO) Q4 2025 Earnings Call Highlights: Na - GuruFocus
Bionano Q4 2025 slides: margins surge 47% as cost cuts offset revenue dip By Investing.com - Investing.com South Africa
Bionano Genomics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Bionano Genomics (BNGO) Reports Q4 2025 Earnings, Sets 2026 Reve - GuruFocus
Bionano Genomics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Bionano Genomics (BNGO) Earnings Transcript - The Globe and Mail
Earnings call transcript: Bionano Genomics’ Q4 2025 results show cost cuts, stock surges By Investing.com - Investing.com South Africa
Bionano Genomics (BNGO) Sees Promising Growth in Optical Genome Mapping - gurufocus.com
Earnings call transcript: Bionano Genomics’ Q4 2025 results show cost cuts, stock surges - Investing.com
Bionano Genomics (BNGO) Reports Q4 Revenue Beat Despite Lower Sa - GuruFocus
Bionano Genomics Inc (BNGO) DEC/2025 Earning Prediction - Intellectia AI
Bionano Genomics Stock Soars As Efficiency Gains Meet Growth Story - Benzinga
BNGO Projects Revenue Growth for FY26 - GuruFocus
Bionano Genomics shares are trading higher af... - benzinga.com
Bionano Genomics 2025 10-K: Revenue $28.5M, EPS $(4.85) - TradingView
Bionano Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Going-concern risk and OGM growth focus at Bionano Genomics (NASDAQ: BNGO) - Stock Titan
Bionano Genomics Sees FY2026 Sales $30.000M-$33.000M vs $35.075M EstBionano Genomics (NASDAQ:BNGO) - benzinga.com
BRIEF-Bionano Genomics Q4 Revenue USD 8 Million - TradingView
Bionano Genomics, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2026 - MarketScreener
[8-K] Bionano Genomics, Inc. Reports Material Event - Stock Titan
Bionano Genomics Surges 21.7% on Strong Technical Signals and Pre-Earnings Optimism – What’s Next for BNGO? - Bitget
United Airlines, AGI And 3 Stocks To Watch Heading Into Monday - Benzinga
Bionano Genomics, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Bionano Genomics, Inc. (BNGO) - Minichart
Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Sahm
Bionano Genomics Inc (BNGO) Stock Price, Quote, News & History - Benzinga
Bionano Genomics Inc expected to post a loss of $1.40 a shareEarnings Preview - TradingView
BNGO PE Ratio & Valuation, Is BNGO Overvalued - Intellectia AI
Bionano Genomics, Inc.: Fundamental Analysis and Financial Ratings | | US09075F3055 - marketscreener.com
Bionano Genomics Inc Stock (BNGO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):